Business · Companies · 12 hrs ago
Faes Farma sales rise 24% as eye division and overseas business expand
Spanish drugmaker Faes Farma reported higher sales in the first nine months of 2026.
Revenue rose 24% to more than €563 million, helped by its new ophthalmology division and international markets.
Sales outside Spain and Portugal increased 76%, with Latin America a major source of growth.
The company’s newer eye-care subsidiaries, SIFI and Edol, contributed 17% of consolidated revenue.
Net profit edged up 1% to €74.3 million, while earnings before interest, tax, depreciation and amortisation rose 17% to €124.4 million.
Revenue from licensing its allergy medicine Bilastina fell 23% after Japan began allowing generic versions.
Faes Farma kept its 2026 growth targets and plans to expand in Latin America, complete the integration of SIFI and Edol, and move production to a new factory in Derio, Spain.
Faes Farma reported a 24% rise in revenue to more than €563 million in the first nine months.
The company said growth was driven by its new ophthalmology division and international subsidiaries, particularly in Latin America.
Net profit rose 1% to €74.3 million, while EBITDA increased 17% to €124.4 million.
Sales outside Spain and Portugal rose 76%, and those operations accounted for 39% of consolidated sales.
Faes Farma kept its 2026 forecast for sales growth of 17% to 19%.
- Who
- Faes Farma, a pharmaceutical group.
- What
- Revenue rose 24% to more than €563 million in the first nine months. Net profit increased 1% to €74.3 million.
- When
- The first nine months of 2026. The results were reported on October 29, 2026.
- Where
- The company’s international markets, especially Latin America, contributed to growth.
- Why
- Growth came from the new ophthalmology division and international subsidiaries. The article also cites a 76% increase in sales outside Spain and Portugal.
This story does not have two clearly opposing sides.
Faes Farma recorded revenue of €627 million for the year.
Revenue exceeded €563 million, up 24% from the same period a year earlier.
Cinco Días reported the company’s nine-month results and its full-year 2026 forecasts.
The company plans to complete the integration of SIFI and Edol and move to its new factory in Derio.
- Revenue
- More than €563 million in the first nine months, up 24%
- Net profit
- €74.3 million, up 1%
- EBITDA
- €124.4 million, up 17%
- International sales
- Sales outside Spain and Portugal rose 76% and made up 39% of consolidated sales
- Latin America
- Sales rose 37% in Mexico, 15% in Ecuador, 14% in Colombia and 13% in Peru
- 2026 sales forecast
- Growth of 17% to 19% over 2025 revenue of €627 million